Amisulpride Modified Release Formulations for Reduced Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current amisulpride formulations for treating psychiatric and mood disorders, particularly bipolar disorder, are associated with significant side effects such as extrapyramidal symptoms, QT interval prolongation, and other adverse events due to high dopamine D2 receptor occupancy, necessitating the development of formulations with reduced side effects and improved safety profiles.
Innovation Solution
Modified release pharmaceutical formulations of non-racemic amisulpride, comprising unequal mixtures of (R)-(+)-amisulpride and (S)-(−)-amisulpride or their pharmaceutically acceptable salts, which provide reduced blood plasma maximum concentrations and total exposure, achieving equivalent dopamine D2 receptor occupancy with lower QT interval prolongation and decreased adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immediate release formulations of amisulpride are used to achieve therapeutic effect, then dopamine D2 receptor occupancy is achieved, but high blood plasma concentrations cause extrapyramidal symptoms and other adverse events
Solution Approach 1:
The patent employs modified release formulations that deliver amisulpride in a controlled, periodic manner rather than as an immediate release. This involves using matrix systems or coated tablets that release the drug gradually over time, maintaining plasma concentrations within the therapeutic window while avoiding the peak concentrations that trigger extrapyramidal symptoms. The periodic release pattern ensures sustained dopamine D2 receptor occupancy without exceeding safe concentration thresholds.
Solution Approach 2:
The invention changes the pharmacokinetic parameters of amisulpride delivery by transitioning from immediate release to modified release formulations. This alters the plasma concentration-time profile, reducing Cmax (maximum concentration) while maintaining or extending the duration of action. The modified release system transforms the drug delivery parameters to achieve therapeutic efficacy at lower peak concentrations, thereby reducing the incidence of concentration-dependent adverse events.
2Reliability
If high doses of amisulpride are administered to ensure therapeutic effect, then dopamine D2 receptor occupancy is maintained, but QT interval prolongation and other serious adverse events increase
Solution Approach 1:
The modified release formulations deliver amisulpride at controlled rates over extended periods, preventing the accumulation that occurs with repeated immediate release dosing. This periodic, controlled delivery maintains stable plasma concentrations that are sufficient for therapeutic effect but remain below the threshold for QT interval prolongation. The sustained release mechanism ensures that even at equivalent or higher total daily doses, the peak concentrations do not reach levels associated with cardiac adverse events.
Solution Approach 2:
The patent introduces a modified release matrix or coating system as an intermediary between the drug and the patient's body. This intermediary controls the rate and pattern of drug release, acting as a buffer that prevents sudden high concentrations from reaching the systemic circulation. The release mechanism mediates the delivery to maintain concentrations in the therapeutic range while filtering out the harmful high-concentration peaks that cause QT prolongation.
3Reliability
If racemic amisulpride is used for treatment, then both enantiomers contribute to therapeutic effect, but both enantiomers contribute to side effects including extrapyramidal symptoms and QT prolongation
Solution Approach 1:
The invention extracts or separates the harmful component from the racemic mixture by using modified release formulations that selectively control the release of individual enantiomers. The patent describes formulations containing unequal amounts of R and S enantiomers, where the release kinetics are designed to optimize the therapeutic contribution of one enantiomer while minimizing the release and systemic exposure to the other enantiomer that contributes more to adverse events. This selective extraction approach maintains efficacy while reducing the harmful burden.
Solution Approach 2:
The patent applies local quality by creating asymmetric compositions within the modified release formulation, where different enantiomers are distributed unevenly or released at different rates. This allows the formulation to have different functional properties at different times or locations in the release profile, optimizing the therapeutic-to-toxic ratio by ensuring that the enantiomer with better safety profile contributes more to the overall effect.
4Object-affected harmful factors
If modified release formulations are used to reduce side effects, then blood plasma Cmax and AUC are reduced, but it must be ensured that equivalent dopamine D2 receptor occupancy is maintained
Solution Approach 1:
The modified release formulations use periodic, controlled release mechanisms to maintain stable plasma concentrations over time. This sustained release pattern ensures that dopamine D2 receptor occupancy remains consistent and therapeutic throughout the dosing interval, even though peak concentrations are lower. The periodic delivery compensates for the lower Cmax by extending the duration of adequate concentration maintenance, thereby preserving receptor occupancy without the harmful peaks.
Solution Approach 2:
The invention employs dynamic release systems that can adapt to physiological conditions, using pH-sensitive or enzyme-triggered mechanisms to optimize release in the gastrointestinal tract. This dynamic approach ensures that the drug is released in a pattern that maintains therapeutic plasma levels and receptor occupancy, adjusting the release rate to match the body's needs while keeping peak concentrations below toxic thresholds.
Data Source
AI summary
Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.